- Home
- VCIG vs NXTC Comparison
VCIG vs NXTC Comparison
Compare VCIG & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- NXTC
- Stock Information
- Founded
- VCIG 2013
- NXTC 2015
- Country
- VCIG Malaysia
- NXTC United States
- Employees
- VCIG N/A
- NXTC N/A
- Industry
- VCIG Diversified Commercial Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- NXTC Health Care
- Exchange
- VCIG Nasdaq
- NXTC Nasdaq
- Market Cap
- VCIG 26.3M
- NXTC 21.6M
- IPO Year
- VCIG 2023
- NXTC 2019
- Fundamental
- Price
- VCIG $0.93
- NXTC $0.72
- Analyst Decision
- VCIG
- NXTC Strong Buy
- Analyst Count
- VCIG 0
- NXTC 2
- Target Price
- VCIG N/A
- NXTC $4.00
- AVG Volume (30 Days)
- VCIG 2.5M
- NXTC 62.2K
- Earning Date
- VCIG 03-04-2025
- NXTC 03-20-2025
- Dividend Yield
- VCIG 48.51%
- NXTC N/A
- EPS Growth
- VCIG N/A
- NXTC N/A
- EPS
- VCIG 7.82
- NXTC N/A
- Revenue
- VCIG $23,548,256.00
- NXTC N/A
- Revenue This Year
- VCIG N/A
- NXTC N/A
- Revenue Next Year
- VCIG N/A
- NXTC N/A
- P/E Ratio
- VCIG $0.12
- NXTC N/A
- Revenue Growth
- VCIG 89.38
- NXTC N/A
- 52 Week Low
- VCIG $0.88
- NXTC $0.66
- 52 Week High
- VCIG $68.60
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- VCIG 39.18
- NXTC 40.34
- Support Level
- VCIG $0.90
- NXTC $0.66
- Resistance Level
- VCIG $1.09
- NXTC $0.79
- Average True Range (ATR)
- VCIG 0.09
- NXTC 0.06
- MACD
- VCIG 0.04
- NXTC 0.00
- Stochastic Oscillator
- VCIG 18.07
- NXTC 42.21
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.